1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (4957)
  2. Meeting Abstract (2007)
  3. Book Section (216)
  4. Conference Paper (122)
  5. Review (79)
  6. Editorial (48)
  7. Book Whole (28)
  8. Research Letter (15)
  9. Correspondence (8)
  10. Miscellaneous (6)
  11. Guidelines (1)
Groups
  1. Molecular Pharmacology and Chemistry Program Faculty (7487)
  2. Sloan Kettering Institute Faculty (7487)
  3. GSK Faculty (4697)
  4. Department of Medicine (2717)
  5. Surgery (2096)
  6. Center for Hematologic Malignancies (1819)

More Groups

People
  1. Murray Brennan (1059)
  2. Steven Larson (957)
  3. Peter Scardino (671)
  4. Michel Sadelain (582)
  5. Samuel Danishefsky (539)
  6. David Scheinberg (499)

More People

Years
  1. 2025 (36)
  2. 2024 (94)
  3. 2023 (122)
  4. 2022 (150)
  5. 2021 (154)
  6. 2020 (162)

More Years

Publications
  1. Journal of Nuclear Medicine (382)
  2. Blood (379)
  3. Cancer Research (340)
  4. Journal of Clinical Oncology (315)
  5. Annals of Surgical Oncology (181)
  6. International Journal of Radiation Oncology, Biology, Physics (176)

More Publications

Publishers
  1. American Association for Cancer Research (712)
  2. Elsevier Inc. (693)
  3. Nature Publishing Group (490)
  4. Springer (467)
  5. American Chemical Society (440)
  6. Elsevier Science, Inc. (405)

More Publishers

Results (7487)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Medical physics in the era of genomic medicine
    Meeting Abstract

    Hricak, H.; Jaffray, D.; Hazle, J.
    Medical Physics (2013)

    Fulltext@MSK | Save
  • Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma
    Meeting Abstract

    Won, E.; Ilson, D.; Kelsen, D. P.; Strong, V. E.; Schoder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J. A.; O'Donoghue, J. A.; Humm, J.; Lyashchenko, S. K.; Haupt, E. C.; Bander, N. H.; Tagawa, S. T.; Holland, J. P.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Kelsen, D. P.; Strong, V. E.; Schöder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.; Ilson, D. H.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study
    Meeting Abstract

    Kelly, K. J.; Yoon, S. S.; Kuk, D.; Qin, L. X.; Dukleska, K.; Chang, K.; DeLaney, T. F.; Brennan, M. F.; Singer, S.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Using (124)I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Gajria, D.; Taldone, T.; Alpaugh, M.; DaGama, E. G.; Uddin, M.; Chiosis, G.; Lewis, J. S.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL
    Meeting Abstract

    Dubrovsky, L.; Brea, E. J.; Veomett, N. J.; Dao, T.; Yan, S.; Liu, C.; Scheinberg, D. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save